Our study demonstrates that FGFR1/MAPK signaling potentially contributes to brachyury activation and suggests that targeting FGFR1/MAPK may represent a useful strategy to suppress brachyury-driven lung cancer progression. The gene discussed is FGFR1; the disease is lung cancer.